Skip to content

Study · Animal study (in vivo) · rat · 2023

9 results

Abaloparatide Maintains Normal Rat Blood Calcium Level in Part Via 1,25-Dihydroxyvitamin D/osteocalcin Signaling Pathway.

Yang Y, Tseng WJ, Wang B

Endocrinology1 Aug 2023Cited by 4 (Europe PMC)

PMID37493045 (opens in a new tab)PMCIDPMC10424883 (opens in a new tab)DOI10.1210/endocr/bqad117 (opens in a new tab)PepBankPUB-37493045
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, abaloparatide significantly increased blood 1,25-dihydroxyvitamin D.

    In plain wordsIn rats, abaloparatide increased blood levels of active vitamin D.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBlood 1,25-dihydroxyvitamin D
    Study

    ratn: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 µg/kg/day · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Our in vivo data showed that ABL treatment (40 µg/kg/day for 7 days) significantly increased rat blood level of 1,25-dihydroxyvitamin D [1,25-(OH)2D] without raising the blood calcium value.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, abaloparatide did not raise blood calcium.

    In plain wordsIn rats, abaloparatide did not raise blood calcium.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBlood calcium
    Study

    ratn: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 µg/kg/day · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Our in vivo data showed that ABL treatment (40 µg/kg/day for 7 days) significantly increased rat blood level of 1,25-dihydroxyvitamin D [1,25-(OH)2D] without raising the blood calcium value.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, abaloparatide significantly increased blood carboxylated osteocalcin.

    In plain wordsIn rats, abaloparatide increased carboxylated osteocalcin in blood.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBlood carboxylated osteocalcin
    Study

    ratn: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ABL also significantly augmented the carboxylated osteocalcin (Gla-Ocn) in the blood and bone that is synthesized by osteoblasts, and increased noncarboxylated Ocn, which is released from the bone matrix to the circulation because of osteoclast activation.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, abaloparatide significantly increased bone carboxylated osteocalcin.

    In plain wordsIn rats, abaloparatide increased carboxylated osteocalcin in bone.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone carboxylated osteocalcin
    Study

    ratn: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ABL also significantly augmented the carboxylated osteocalcin (Gla-Ocn) in the blood and bone that is synthesized by osteoblasts, and increased noncarboxylated Ocn, which is released from the bone matrix to the circulation because of osteoclast activation.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats, abaloparatide increased noncarboxylated osteocalcin released into circulation from bone matrix.

    In plain wordsIn rats, abaloparatide increased noncarboxylated osteocalcin released from bone into blood.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseNoncarboxylated osteocalcin
    Study

    ratn: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ABL also significantly augmented the carboxylated osteocalcin (Gla-Ocn) in the blood and bone that is synthesized by osteoblasts, and increased noncarboxylated Ocn, which is released from the bone matrix to the circulation because of osteoclast activation.
  6. 06LabIn vitro (cells)Mechanism

    In rat osteoblast-like cells, abaloparatide had little direct effect on 1,25-dihydroxyvitamin D synthesis.

    In plain wordsIn cells, abaloparatide had little direct effect on active vitamin D production.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeDirect 1,25-dihydroxyvitamin D synthesis
    Study

    ratn: not reported in source

    Rat osteoblast-like cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 nM · 24 hoursAs given in this study (rat).

    Source sentences

    Summary
    The in vitro data showed that ABL (10 nM for 24 hours) had little direct effects on 1,25-(OH)2D synthesis and Gla-Ocn formation in nonrenal cells (rat osteoblast-like cells).
  7. 07LabIn vitro (cells)Mechanism

    In rat osteoblast-like cells, abaloparatide had little direct effect on carboxylated osteocalcin formation.

    In plain wordsIn cells, abaloparatide had little direct effect on carboxylated osteocalcin formation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeDirect carboxylated osteocalcin formation
    Study

    ratn: not reported in source

    Rat osteoblast-like cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 nM · 24 hoursAs given in this study (rat).

    Source sentences

    Summary
    The in vitro data showed that ABL (10 nM for 24 hours) had little direct effects on 1,25-(OH)2D synthesis and Gla-Ocn formation in nonrenal cells (rat osteoblast-like cells).
  8. 08LabIn vitro (cells)Mechanism

    In rat osteoblast-like cells supplied with 25-hydroxyvitamin D, abaloparatide significantly promoted 1,25-dihydroxyvitamin D formation.

    In plain wordsIn cells supplied with a vitamin D precursor, abaloparatide increased active vitamin D formation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSubstrate-dependent active vitamin D formation
    Study

    ratn: not reported in source

    Rat osteoblast-like cells with 25-hydroxyvitamin D substrate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, ABL significantly promoted both 1,25-(OH)2D and Gla-Ocn formation when 25-hydroxyvitamin D, the substrate of 1α-hydroxylase, was added to the cells.
    1 context sentence
    Summary · context
    The in vitro data showed that ABL (10 nM for 24 hours) had little direct effects on 1,25-(OH)2D synthesis and Gla-Ocn formation in nonrenal cells (rat osteoblast-like cells).
  9. 09LabIn vitro (cells)Mechanism

    In rat osteoblast-like cells supplied with 25-hydroxyvitamin D, abaloparatide significantly promoted carboxylated osteocalcin formation.

    In plain wordsIn cells supplied with a vitamin D precursor, abaloparatide increased carboxylated osteocalcin formation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSubstrate-dependent carboxylated osteocalcin formation
    Study

    ratn: not reported in source

    Rat osteoblast-like cells with 25-hydroxyvitamin D substrate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, ABL significantly promoted both 1,25-(OH)2D and Gla-Ocn formation when 25-hydroxyvitamin D, the substrate of 1α-hydroxylase, was added to the cells.
    1 context sentence
    Summary · context
    The in vitro data showed that ABL (10 nM for 24 hours) had little direct effects on 1,25-(OH)2D synthesis and Gla-Ocn formation in nonrenal cells (rat osteoblast-like cells).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.